Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Intracerebral Lesions with Abatacept in a CTLA4-Haploinsufficient Patient

  • Letter to Editor
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12):1410–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204):1623–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541–7.

    Article  PubMed  CAS  Google Scholar 

  4. Shields CL, Say EAT, Mashayekhi A, Garg SJ, Dunn JP, Shields JA. Assessment of CTLA-4 deficiency-related autoimmune choroidopathy response to abatacept. JAMA Ophthalmol. 2016;134(7):844–6.

    Article  PubMed  Google Scholar 

  5. Lee S, Moon JS, Lee C-R, Kim H-E, Baek S-M, Hwang S, et al. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol. 2016;137(1):327–30.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Prof Dr Eleonora Aronica and Dr Maurits van Montfoort for providing pathology biopsy specimens and their expertise regarding the interpretation and Prof Dr Ineke ten Berge for critically reading the manuscript.

Author information

Authors and Affiliations

  1. Department of Experimental Immunology, Academic Medical Center, Amsterdam, the Netherlands

    Ester M. van Leeuwen

  2. Department of Hematopoiesis, Sanquin Research, Amsterdam, the Netherlands

    Eloy Cuadrado

  3. Department of Internal Medicine, OLVG, Amsterdam, the Netherlands

    Anke M. Gerrits

  4. Department of Neurology, Academic Medical Center, Amsterdam, the Netherlands

    Esther Witteveen

  5. Department of Internal Medicine, Division of Infectious Diseases, Academic Medical Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands

    Godelieve J. de Bree

Authors
  1. Ester M. van Leeuwen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eloy Cuadrado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anke M. Gerrits
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Esther Witteveen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Godelieve J. de Bree
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Godelieve J. de Bree.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Electronic Supplementary Material

Supplementary table 1

(DOCX 25 kb)

Supplementary figure 1

FACS plots showing the expression of FOXP3 and CD25 (top panels), CD127 and CD25 (middle panels), and Helios and FOXP3 (bottom panels) on gated CD4+ T cells from controls (black) and the patient (in red) before and after treatment with abatacept. (PPTX 140 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van Leeuwen, E.M., Cuadrado, E., Gerrits, A.M. et al. Treatment of Intracerebral Lesions with Abatacept in a CTLA4-Haploinsufficient Patient. J Clin Immunol 38, 464–467 (2018). https://doi.org/10.1007/s10875-018-0511-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-018-0511-1

Search

Navigation